Merck (MRK) Other Accumulated Expenses (2009 - 2026)

Merck (MRK) has reported Other Accumulated Expenses for 18 consecutive years, with $14.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses rose 1.54% year-over-year to $14.7 billion in Q2 2026; TTM through Jun 2026 was $14.7 billion, a 1.54% increase from a year earlier, with the FY2025 full-year figure at $14.5 billion, down 7.81% from the prior year.
• Other Accumulated Expenses was $14.7 billion for Q2 2026 at Merck, up from $14.5 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $16.5 billion in Q3 2024 and troughed at $12.8 billion in Q1 2025.
• A 5-year average of $14.5 billion and a median of $14.5 billion in 2025 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses climbed 17.97% in 2022 and declined 9.43% in 2025, its largest moves.
• Over 5 years, Other Accumulated Expenses stood at $14.2 billion in 2022, then advanced by 11.35% to $15.8 billion in 2023, then fell by 0.46% to $15.7 billion in 2024, then dropped by 7.81% to $14.5 billion in 2025, then advanced by 1.78% to $14.7 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $14.7 billion (Q2 2026), $14.5 billion (Q1 2026), and $14.5 billion (Q4 2025), per Business Quant data.